AcquisitionOther
ImmunoGen, Inc. acquired ImmunoGen, including its Flagship Cancer Therapy ELAHERE®
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
ImmunoGen, Inc. -> ImmunoGen, including its Flagship Cancer Therapy ELAHERE® · $31.26
Additionally, ImmunoGen's follow-on pipeline of promising next-generation ADCs further complements AbbVie's ADC platform and existing programs.
Open source record (SEC) ↗